Lantern Pharma Q2 Results and LP-300 Clinical Trial Update
PremiumCompany AnnouncementsLantern Pharma Q2 Results and LP-300 Clinical Trial Update
3M ago
Lantern Pharma reports Q2 EPS (46c), one estimate (55c)
Premium
The Fly
Lantern Pharma reports Q2 EPS (46c), one estimate (55c)
3M ago
Lantern Pharma highlights ‘promising’ prelinical results of LP-184
Premium
The Fly
Lantern Pharma highlights ‘promising’ prelinical results of LP-184
3M ago
Lantern Pharma reports Q1 EPS (51c) , one estimate (43c)
PremiumThe FlyLantern Pharma reports Q1 EPS (51c) , one estimate (43c)
6M ago
Lantern Pharma enters AI-driven collaboration with Oregon Therapeutics
Premium
The Fly
Lantern Pharma enters AI-driven collaboration with Oregon Therapeutics
7M ago
Lantern Pharma receives regulatory approval to expand Harmonic trial
Premium
The Fly
Lantern Pharma receives regulatory approval to expand Harmonic trial
7M ago
LTRN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-EarningsLTRN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
9M ago
Lantern Pharma generates new class of ADCs with cryptophycin drug-payload
Premium
The Fly
Lantern Pharma generates new class of ADCs with cryptophycin drug-payload
9M ago
Lantern Pharma receives Orphan Drug Designation from FDA for LP-284
Premium
The Fly
Lantern Pharma receives Orphan Drug Designation from FDA for LP-284
12M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100